Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia

Takashi Kumagai, Eri Matsuki, Koiti Inokuchi, Kazuteru Ohashi, Atsushi Shinagawa, Jin Takeuchi, Chikashi Yoshida, Shinichiro Okamoto, Hisashi Wakita, Yasuji Kozai, Yukari Shirasugi, Shin Fujisawa, Osamu Iwase, Shingo Yano, Kaichi Nishiwaki, Koji Oba, Junichi Sakamoto, Hisashi Sakamaki

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Lymphocytosis in response to dasatinib for chronic myelogenous leukemia (CML) may be associated with favorable response. However, it occurs at varying times and in a limited subset of patients. To identify early clinical markers for favorable responses applicable to all patients with or without lymphocytosis, we prospectively analyzed lymphocyte profiles of 50 Japanese CML patients treated with dasatinib after intolerance/resistance to imatinib. Although absolute lymphocyte counts did not differ significantly until 3 months between patients with complete molecular response (CMR) at 12 months and those without it, relative increases in lymphocyte compared with baselines differed significantly from 1 month. Patients with relative lymphocyte counts >150% at 1 month or >200% at 3 months had higher CMR rates at 12 months than others (57.9 vs. 23.3%, P = 0.015, and 76.5 vs. 16.1%, P < 0.0001, respectively). A relative increase in lymphocyte subset of CD57+CD14-, CD8+T, or NK cells >200% at 1 month was also significantly associated with a higher CMR rate. There were significant negative correlations between relative lymphocyte increases and BCR/ABL transcript levels. CD57 +CD14- cells were a highly specific focus of proliferation. Relative increases in lymphocyte count and its subsets from 1 month are reliable early markers of favorable responses to dasatinib.

Original languageEnglish
Pages (from-to)41-52
Number of pages12
JournalInternational journal of hematology
Volume99
Issue number1
DOIs
Publication statusPublished - 2014 Jan

Keywords

  • CML
  • Dasatinib
  • Lymphocytosis

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this

    Kumagai, T., Matsuki, E., Inokuchi, K., Ohashi, K., Shinagawa, A., Takeuchi, J., Yoshida, C., Okamoto, S., Wakita, H., Kozai, Y., Shirasugi, Y., Fujisawa, S., Iwase, O., Yano, S., Nishiwaki, K., Oba, K., Sakamoto, J., & Sakamaki, H. (2014). Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. International journal of hematology, 99(1), 41-52. https://doi.org/10.1007/s12185-013-1483-9